Recent Updates
Recently added Catalysts
SMMT

Summit Therapeutics to Present at the 2019 BIO Investor Forum

Key Takeaway: Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2019 BIO Investor Forum Oxford, UK, and Cambridge, MA, US, 16 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, wil

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1236%
120-day peak, hindsight
Typical move
47.7%
average across 2 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
Ivonescimab
Phase 3 · Non-Small Cell Lung Cancer

Full Press Release Details

Summit Therapeutics plc
(‘Summit’ or the ‘Company’)
Summit Therapeutics to Present at the 2019 BIO Investor Forum
Oxford, UK, and Cambridge, MA, US, 16 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2019 BIO Investor Forum on 22 October 2019 at 10:45am PDT in San Francisco.
A live webcast of the presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.
About Summit Therapeutics
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6652
Erin Anthoine summit@mslgroup.com
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina Virji summit@consilium-comms.com
Lindsey Neville
Last updated: Oct 16, 2019